02179.HK
Jiangsu Recbio Technology Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 4.00
+0.00%Year over year
Reported trailing growth
- Revenue
- -68.1%
- EBITDA
- +34.4%
- EBIT
- +28.3%
- EPS
- +43.4%
- Free cash flow
- +15.0%
- Operating cash flow
- -1.0%
Forward estimates
Based on analyst estimates
- Revenue
- +9.8%
- EBITDA
- +5.7%
- EPS
- +13.7%
Three-year CAGR
- Revenue
- +32.5%
- EBITDA
- +1.5%
- EBIT
- -3.0%
- Net income
- -5.7%
- EPS
- +3.4%
- Free cash flow
- +5.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026